Skip to main content
. 2018 Aug 30;10:477–491. doi: 10.2147/CEOR.S171560

Table 1.

Approved indications and currently approved and reimbursed treatments for secukinumab in Italy, along with their posology

Secukinumab indication Currently approved and reimbursed treatments in Italy (maintenance year)
PsO: moderate-to-severe plaque Pso in adult patients who are candidates for systemic therapy or phototherapy Secukinumab 300 mg monthly, adalimumab 40 mg every 2 weeks, etanercept 50 mg once weekly, ustekinumab 45 mg every 12 weeks, ustekinumab 90 mg every 12 weeks, infliximab 5 mg/kg, every 8 weeks
PsA: active PsA in adult patients when the response to previous DMARD therapy has been inadequate Secukinumab 300 mg monthly for patients with concomitant moderate-to-severe plaque Pso or who are anti-TNFα IR, secukinumab 150 mg monthly for all other patients, adalimumab 40 mg every 2 weeks, certolizumab 200 mg every 2 weeks, etanercept 50 mg once weekly, golimumab 50 mg monthly, ustekinumab 45 mg every 12 weeks, infliximab 5 mg/kg every 8 weeks, apremilasta 30 mg twice daily
AS: active AS in adults who have responded inadequately to conventional therapy Secukinumab 150 mg monthly, adalimumab 40 mg every 2 weeks, certolizumab 200 mg every 2 weeks, etanercept 50 mg once weekly, golimumab 50 mg monthly, infliximab 5 mg/kg every 8 weeks

Notes: Posology was obtained from products SmPC; please refer to last approved SmPC for loading doses where applied. Last reimbursement status for each drug can be found on the Italian Official Journal website.72

a

Not reimbursed in Pso, reimbursed in PsA for patients which are intolerant or inadequate to biologic therapies.

Abbreviations: AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; IR, inadequate responders; PsA, psoriatic arthritis; Pso, psoriasis; SmPC, summary of product characteristics; TNF, tumor necrosis factor.